IM8.{13-15,17-19} | Hypertension Management and Follow-up — Summary & Reflection

KEY TAKEAWAYS

Hypertension management — key framework:

• When to treat (IM8.13): ACC/AHA 2017: Stage 1 HTN + ASCVD risk <10% → lifestyle 3 months first; Stage 1 + ASCVD ≥10% or high-risk comorbidity → immediate drug therapy; Stage 2 HTN (≥140/≥90) → all patients, immediate. Indian guidelines (IGH-IV): threshold 140/90 mmHg; high-risk target <130/80 mmHg.
• Lifestyle modification (IM8.15): Sodium restriction (target <5 g salt/day, reduces SBP 4–6 mmHg); weight loss (~1 mmHg/kg); aerobic exercise 150 min/week (reduces SBP 4–9 mmHg); alcohol <2 units/day; DASH diet (reduces SBP 8–14 mmHg); tobacco cessation (risk reduction, not BP).
• Drug classes (IM8.13): A (ACE/ARB — compelling: diabetes, CKD, HFrEF, post-MI; contraindicated: bilateral RAS, pregnancy), C (CCB — compelling: elderly, ISH, angina, Black patients; avoid verapamil/diltiazem in HFrEF), D (thiazide-like — compelling: elderly, ISH, Black patients; avoid in gout), B (beta-blocker — compelling: angina, HFrEF, post-MI, AF; avoid as first-line uncomplicated HTN). Preferred combination: A+C; avoid A+A.
• Hypertensive emergency (IM8.14): End-organ damage present → ICU, IV agent, MAP reduction ≤20–25% in 1 hour (except aortic dissection: SBP <120 mmHg in 20 min; ischaemic stroke: do not treat unless ≥220/120 or pre-tPA). Key agents: nicardipine (encephalopathy, stroke), labetalol (dissection, eclampsia, encephalopathy), nitroglycerin (ACS, pulmonary oedema), hydralazine (eclampsia).
• Adherence and counselling (IM8.15, IM8.17): Explain silent risk; use fixed-dose once-daily combinations; actively screen for side effects; involve family; use plain language ('tablet for blood pressure like taking a vitamin daily, but specifically for heart protection').
• Specialist referral (IM8.19): Secondary hypertension, resistant hypertension, hypertensive emergency, CKD, HFrEF, hypertension in pregnancy, children, or when ABPM needed.

REFLECT

Reflect on the gap between what we know and what we achieve in hypertension care in India. Treatment rates are improving but remain poor — only 15% of hypertensive Indians have controlled BP. The tools are available, the drugs are inexpensive, and the evidence is unambiguous. Yet the majority of patients remain uncontrolled. As a physician entering practice in India, what systemic factors would you identify as the most important to address — and what is within YOUR control as a clinician in a district hospital or urban clinic? Think also about the patient you will counsel this week who says 'I feel fine, so why do I need this tablet?' How would you frame that conversation to move from compliance (doing what the doctor says) to informed adherence (understanding why and making a personal commitment)? The art of managing a silent chronic disease lies entirely in communication — and that begins with the conversations you have as a student.